The Sputnik vaccine figures only the second to be published from a late stage human trial, coming hot on the heels of American pharmaceutical giant Pfizer earlier this week on its own promising figure of 90% effectiveness.

The Sputnik research comes from the 1st 16,000 trial participants to receive both shots of the two dose vaccine.

Analysis was conducted after 20 participants in the trial developed covert 19 and then examined how many had received the vaccine vs placebo.

However, outside experts said knowledge about the trials, design and protocol was sparse, making it difficult to interpret the figures.

Yeah, the Russian direct investment fund of the main backers off the Sputnik vaccine.

They remained positive and say it was the sort of news developers would talk about one day with their grandchildren.

The Russian trial announced it will continue for six more months, and data from the study will also be published in a leading international medical journal following a peer review.